The relative contribution of the CYP2C19*2 polymorphism in the low responsiveness to clopidogrel in the VASP-02 study

被引：0
|
作者：
Aleil, B. [1 ]
De Poli, F. [2 ]
Zaehringer, M. [1 ]
Collet, J. P. [3 ,4 ]
Montalescot, G. [3 ,4 ]
Leon, C. [5 ]
Cazenave, J. P. [5 ]
Dickele, M. C. [2 ]
Monassier, J. P. [6 ]
Gachet, C. [5 ]
机构：
[1] Clin Orangerie, Strasbourg, France
[2] Ctr Hosp Gen, Serv Cardiol, Haguenau, France
[3] Hop La Pitie Salpetriere, AP HP, Inst Cardiol, Paris, France
[4] Hop La Pitie Salpetriere, AP HP, INSERM, U856, Paris, France
[5] Univ Strasbourg, INSERM, UMR S 949, Etab Francais Sang Alsace, Strasbourg, France
[6] Hop Emile Muller, Serv Cardiol, Mulhouse, France
来源：
EUROPEAN HEART JOURNAL | 2009年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：327 / 328
页数：2
相关论文
共 50 条
  • [31] Prediction of Clopidogrel Low Responders by a Rapid CYP2C19 Activity Test
    Tazaki, Junichi
    Jinnai, Toshikazu
    Tada, Tomohisa
    Kato, Yoshihiro
    Makiyama, Takeru
    Ikeda, Tomoyuki
    Yamane, Keiichiro
    Naruse, Yumiko
    Takahashi, Kanako
    Watanabe, Haruyo
    Kimura, Takeshi
    Horiuchi, Hisanori
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2012, 19 (02) : 186 - 193
  • [32] CYP2C19 gene polymorphism in Ningxia
    Zhen Yang
    Yunqian Xie
    Daya Zhang
    Yan Zou
    Ximei Li
    Runxiang Chen
    Xiaodong Zhang
    Shiju Chen
    Feihu Bai
    Pharmacological Reports, 2023, 75 : 705 - 714
  • [33] CYP2C19 gene polymorphism in Ningxia
    Yang, Zhen
    Xie, Yunqian
    Zhang, Daya
    Zou, Yan
    Li, Ximei
    Chen, Runxiang
    Zhang, Xiaodong
    Chen, Shiju
    Bai, Feihu
    PHARMACOLOGICAL REPORTS, 2023, 75 (03) : 705 - 714
  • [34] The effect of CYP2C19 genotype on the platelet responsiveness to clopidogrel in healthy Korean subjects.
    Cho, D.
    Yeo, C.
    Oh, M.
    Shon, J.
    Kim, E.
    Shin, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 : S69 - S69
  • [35] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Imad Zalloum
    Nancy Hakooz
    Tawfiq Arafat
    Molecular Biology Reports, 2012, 39 : 4195 - 4200
  • [36] Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects
    Fontana, P.
    Hulot, J.-S.
    De Moerloose, P.
    Gaussem, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (10) : 2153 - 2155
  • [37] CYP2C19*2 polymorphism influenced response to clopidogrel treatment but was not related to restenosis in atherosclerotic smokers
    da Costa, I. R.
    Borges, K. F.
    dos Santos, T. R.
    Bento, I. A.
    Siqueira, B. O.
    Silva, K. S. F. E.
    Barbosa, A. M.
    Campedelli, F. L.
    Lagares, M. H.
    Gianotti, L. C. A.
    de Souza, F. O.
    Lima, I. B.
    Vilarinho, U. S.
    Moura, K. K. V. O.
    GENETICS AND MOLECULAR RESEARCH, 2020, 19 (03): : 1 - 8
  • [38] Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome
    Jirungda, Sornsith
    Pussadhamma, Burabha
    Komanasin, Nantarat
    Senthong, Vichai
    Leuangwatthananon, Wit
    CORONARY ARTERY DISEASE, 2020, 31 (03) : 266 - 272
  • [39] The Effect of CYP2C19 and Nongenetic Factors on Clopidogrel Responsiveness in the MENA Region: A Systematic Review
    Ali, Zainab
    Elewa, Hazem
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2019, 25
  • [40] THE CYP 2C19*2 AND CYP2C19*17 POLYMORPHISMS PLAY A VITAL ROLE IN PLATELET RESPONSIVENESS TO CLOPIDOGREL AFTER PERCUTANEOUS CORONARY INTERVENTION: A PHARMACOGENOMIC STUDY
    Saydam, F.
    Degirmenci, I.
    Birdane, A.
    Ozdemir, M.
    Ulus, T.
    Ozbayer, C.
    Colak, E.
    Ata, N.
    Gunes, H. V.
    CLINICAL THERAPEUTICS, 2015, 37 (08) : E48 - E48
12345